NHC National Healthcare (NHC) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-skilled nursing care facilities · CIK 0001047335
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
135
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $4.2M priced
What the filings say about NHC
Insiders, 180 days
-$8.7M net sold
1 buyer · 9 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$600.8K
1 notice
National Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NATIONAL HEALTHCARE CORP insiders sold a net $8.7M of stock across 46 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 45.1% of the 10,725 shares held after it.
- 4 other insiders sold within 30 days.
- 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr.VP Patient Srvcs Dodson Vicki L sold about $1.1M of NHC on Sep 22, 2026; 4 other insiders sold within 30 days and 135 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 4, 2024.
- The trade is 29.4% of the 23,183 shares held after it.
- 5 other insiders sold within 30 days.
- 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, CFO KIDD BRIAN F sold about $1.5M of NHC on Sep 11, 2026, the largest insider sale at the company since 2024; 5 other insiders sold within 30 days and 135 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.7% of the 12,127 shares held after it.
- 5 other insiders sold within 30 days.
- 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP & General Counsel McCreary Josh A sold about $127.2K of NHC on Sep 10, 2026; 5 other insiders sold within 30 days and 135 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.0% of the 11,338 shares held after it.
- 5 other insiders sold within 30 days.
- 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP & General Counsel McCreary Josh A sold about $176.6K of NHC on Sep 10, 2026; 5 other insiders sold within 30 days and 135 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.8% of the 10,047 shares held after it.
- 5 other insiders sold within 30 days.
- 135 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP & General Counsel McCreary Josh A sold about $290.6K of NHC on Sep 10, 2026; 5 other insiders sold within 30 days and 135 funds added in the latest 13F quarter.46 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$8.7M over 180 days
-$5.6M over 90 days
below 65% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
135 funds bought in last quarter
more than 53% of Healthcare Services
Revenue
+17.4% year over year
more than 65% of Healthcare Services
Margin
8.2% net margin
more than 82% of Healthcare Services
Buybacks
$23.6M repurchased, FY to 2026-06-30
below 61% of Healthcare Services
Short interest
6.4% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30
more than 67% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NHC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+93.4%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NHC: institutional holders (13F)
13F holdings, latest reported quarter
1,975,785 sh
$417.6M
$217.4M
929,692 sh
$196.5M
809,224 sh
$171.0M
730,573 sh
$154.4M
Congress trades in NHC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NHC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
McCreary Josh A
Filed 2026-09-10
$600.8K
NHC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
LIVE OAK HEALTH SCIENCES FUND
$2.2M position · as of 2026-07-31
3.9%
Saratoga Health & Biotechnology Fund
$389.5K position · as of 2026-05-31
3.7%
ALPS | OShares U.S. Small-Cap Quality Dividend ETF
$28.3M position · as of 2026-05-31
3.2%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.5M position · as of 2026-06-30
1.8%
FT Vest SMID Rising Dividend Achievers Target Income ETF
$11.3M position · as of 2026-07-31
1.2%
Hartford Multifactor Small Cap ETF
$762.6K position · as of 2026-07-31
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Stephen F. Flatt
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$1.6M
$2.4M
$971.2K
+22%
+43%
2022
$1.2M
$1.0M
$696.9K
-24%
+40%
2021
$2.2M
$2.1M
$1.3M
-17%
+43%
2020
$1.3M
$786.7K
$760.4K
-21%
+13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $8.7M sold by insiders over 180 days, 135 funds added last quarter, $600.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
NHC financials
Revenue growth
+17.4%
XBRL, annual
Net margin
8.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NHC
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $1.1B |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $1.1B |
| Jun 2026 | $408.0M |
| Mar 2026 | $381.8M |
| Dec 2025 | $386.5M |
| Sep 2025 | $382.7M |
| Jun 2025 | $374.9M |
| Mar 2025 | $373.7M |
| Dec 2024 | $369.4M |
| Sep 2024 | $340.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+9.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NHC
| FY Dec 2025 | +7.9% |
| FY Dec 2024 | +7.8% |
| FY Dec 2023 | +5.9% |
| FY Dec 2022 | +2.1% |
| FY Dec 2021 | +12.9% |
| Jun 2026 | +9.9% |
| Mar 2026 | +9.4% |
| Dec 2025 | +6.4% |
| Sep 2025 | +10.3% |
| Jun 2025 | +6.3% |
| Mar 2025 | +8.6% |
| Dec 2024 | +1.6% |
| Sep 2024 | +12.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$146.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NHC
| FY Dec 2025 | $148.6M |
| FY Dec 2024 | $79.7M |
| FY Dec 2023 | $83.3M |
| FY Dec 2022 | -$21.5M |
| FY Dec 2021 | $23.0M |
| Jun 2026 | $30.7M |
| Mar 2026 | $52.9M |
| Dec 2025 | $6.4M |
| Sep 2025 | $56.5M |
| Jun 2025 | $52.6M |
| Mar 2025 | $33.1M |
| Dec 2024 | $4.6M |
| Sep 2024 | $28.6M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity NHC
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | 0.14x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.07x |
| Jun 2025 | 0.11x |
| Mar 2025 | 0.13x |
| Dec 2024 | 0.14x |
| Sep 2024 | 0.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt NHC
| FY Dec 2025 | 4.63x |
| FY Dec 2024 | 0.78x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 4.63x |
| Sep 2025 | 2.48x |
| Jun 2025 | 1.36x |
| Mar 2025 | 1.02x |
| Dec 2024 | 0.78x |
| Sep 2024 | 0.88x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+13.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NHC
| FY Dec 2025 | +11.7% |
| FY Dec 2024 | +10.8% |
| FY Dec 2023 | +7.5% |
| FY Dec 2022 | +2.5% |
| FY Dec 2021 | +16.3% |
| Jun 2026 | +13.1% |
| Mar 2026 | +11.8% |
| Dec 2025 | +11.7% |
| Sep 2025 | +9.9% |
| Jun 2025 | +10.7% |
| Mar 2025 | +11.2% |
| Dec 2024 | +10.8% |
| Sep 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NHC
| FY Dec 2025 | +7.9% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +1.7% |
| FY Dec 2021 | +10.0% |
| Jun 2026 | +9.1% |
| Mar 2026 | +8.0% |
| Dec 2025 | +7.9% |
| Sep 2025 | +6.5% |
| Jun 2025 | +7.2% |
| Mar 2025 | +7.5% |
| Dec 2024 | +7.2% |
| Sep 2024 | +8.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.2%
operating income after a 22.9% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital NHC
| FY Dec 2025 | +9.9% |
| FY Dec 2024 | +6.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +11.2% |
| Mar 2026 | +10.5% |
| Dec 2025 | +9.9% |
| Sep 2025 | +9.6% |
| Jun 2025 | +9.0% |
| Mar 2025 | +7.8% |
| Dec 2024 | +6.8% |
| Sep 2024 | +6.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+11.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NHC
| FY Dec 2025 | +10.0% |
| FY Dec 2024 | +7.5% |
| FY Dec 2023 | +5.3% |
| FY Dec 2022 | +2.9% |
| FY Dec 2021 | +4.6% |
| Jun 2026 | +11.2% |
| Mar 2026 | +10.1% |
| Dec 2025 | +10.0% |
| Sep 2025 | +9.5% |
| Jun 2025 | +9.6% |
| Mar 2025 | +8.7% |
| Dec 2024 | +7.5% |
| Sep 2024 | +6.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
26.58x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing NHC
| FY Dec 2025 | 17.90x |
| FY Dec 2024 | 16.47x |
| FY Dec 2023 | 21.29x |
| FY Dec 2022 | 41.03x |
| FY Dec 2021 | 7.57x |
| Jun 2026 | 23.80x |
| Mar 2026 | 20.32x |
| Dec 2025 | 17.90x |
| Sep 2025 | 18.78x |
| Jun 2025 | 15.97x |
| Mar 2025 | 13.43x |
| Dec 2024 | 16.47x |
| Sep 2024 | 15.74x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$3.7B
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value NHC
| FY Dec 2025 | $2.1B |
| FY Dec 2024 | $1.7B |
| FY Dec 2023 | $1.3B |
| FY Dec 2022 | $854.3M |
| FY Dec 2021 | $940.3M |
| Jun 2026 | $3.3B |
| Mar 2026 | $2.4B |
| Dec 2025 | $2.1B |
| Sep 2025 | $1.8B |
| Jun 2025 | $1.7B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.7B |
| Sep 2024 | $2.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.0%
TTM free cash flow over market value at close 2026-10-23
FCF yield NHC
| FY Dec 2025 | +7.0% |
| FY Dec 2024 | +4.8% |
| FY Dec 2023 | +5.9% |
| FY Dec 2022 | -2.4% |
| FY Dec 2021 | +2.2% |
| Jun 2026 | +4.4% |
| Mar 2026 | +6.8% |
| Dec 2025 | +7.0% |
| Sep 2025 | +7.8% |
| Jun 2025 | +7.2% |
| Mar 2025 | +7.6% |
| Dec 2024 | +4.8% |
| Sep 2024 | +4.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.82x
P/E over trailing EPS growth of 33%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing NHC
| FY Dec 2025 | 1.03x |
| FY Dec 2024 | 0.33x |
| FY Dec 2023 | 0.11x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 0.73x |
| Mar 2026 | 1.48x |
| Dec 2025 | 1.03x |
| Sep 2025 | n/a |
| Jun 2025 | 1.25x |
| Mar 2025 | 0.43x |
| Dec 2024 | 0.33x |
| Sep 2024 | 0.09x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2024-09 | 2023-12 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | n/a | $1.1B |
| Operating income | $128.4M | $89.9M | n/a | $57.5M |
| Net income | $120.0M | $101.9M | n/a | $66.8M |
| EPS (diluted) | 7.67 | 6.53 | n/a | 4.34 |
| Operating cash flow | $185.1M | $107.3M | n/a | $111.2M |
| Cash | $92.8M | $76.1M | n/a | $107.1M |
| Long-term debt | $32.5M | $129.5M | $129.5M | $0 |
| Buybacks | $14.7M | $13.5M | n/a | $2.5M |
| Dividends paid | $38.7M | $37.0M | n/a | $35.6M |
SEC XBRL, fiscal years, as known on 2026-10-27
NHC Stock Sonar score 6/7 axes
Find similar shapesCompareNHC ranks highest on financial health (99th percentile) and profitability (70th), and lowest on insider conviction (47th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NHC filings, in plain words
Are National Healthcare insiders buying or selling NHC?
In the 180 days to 2026-10-27, National Healthcare insiders were net sellers, a net $8.7M: $174.9K of purchases and $8.9M of sales reported on Form 4, by 1 buyer and 9 sellers.
Are there planned insider sales of NHC?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $600.8K of stock; the latest, by McCreary Josh A, was filed 2026-09-10.
Read the full summary
In the 180 days to 2026-10-27, National Healthcare insiders were net sellers of NHC, a net $8.7M across purchases and sales reported on Form 4 by 1 buyer and 9 sellers. Sales outweighed purchases more than tenfold by value. None of the 19 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $600.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
